Delving into the Latest Updates on Riviciclib with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

+ [3]

Target

CDK1 x CDK4 x CDK9

Action

inhibitors

Mechanism

CDK1 inhibitors(Cyclin-dependent kinase 1 inhibitors), CDK4 inhibitors(Cyclin-dependent kinase 4 inhibitors), CDK9 inhibitors(Cyclin-dependent kinase 9 inhibitors)

Therapeutic Areas

Digestive System DisordersMouth and Tooth DiseasesNeoplasms+ [6]

Active Indication-

Inactive Indication

Advanced cancerLocally Advanced Head and Neck Squamous Cell CarcinomaLocally Advanced Melanoma+ [9]

Originator Organization

Piramal Phytocare Ltd.

Active Organization-

Inactive Organization

Piramal Enterprises Ltd.

Piramal Phytocare Ltd.

Drug Highest PhaseDiscontinuedPhase 3

First Approval Date-

Regulation-

Login to view timeline

Structure/Sequence

Molecular FormulaC21H21Cl2NO5

InChIKeyOOVTUOCTLAERQD-OJMBIDBESA-N

CAS Registry920113-03-7

View All Structures (2)

P276-00 is a novel, potent, small-molecule, flavone-derived Cdk 4 D1, Cdk1 B, and Cdk9 T inhibitor, with potent cytotoxic effects against chemosensitive and chemoresistant cancer cell lines.This study is planned to compare efficacy of the standard chemotherapy regimen of gemcitabine and carboplatin when administered with or without P276-00 in subjects with advanced triple negative breast cancer.

Start Date01 Aug 2011

Sponsor / Collaborator

Piramal Enterprises Ltd.

NCT00843050

/ TerminatedPhase 2

Single-Arm, Open-Label, Multicenter Phase II Study to Evaluate the Efficacy and Safety of P276-00 in Patients With Relapsed and/or Refractory Mantle Cell Lymphoma

The purpose of this study is to determine whether P276-00 is safe and effective in treatment of Mantle Cell Lymphoma that is recurred after or not responding to at least one previous line of treatment.

Start Date01 Nov 2009

Sponsor / Collaborator

Piramal Enterprises Ltd.

100 Clinical Results associated with Riviciclib

Login to view more data

100 Translational Medicine associated with Riviciclib

Login to view more data

100 Patents (Medical) associated with Riviciclib

Login to view more data

57

Literatures (Medical) associated with Riviciclib

01 Nov 2024·Molecular Neurobiology

Based on Virtual Screening and Simulation Exploring the Mechanism of Plant-Derived Compounds with PINK1 to Postherpetic Neuralgia

Article

Author: Feng, Yi ; Guo, Wenjing ; Zhang, Bo ; Liu, Minchen ; Zhang, Jiquan

Accumulating evidence strongly supports that PINK1 mutation can mediate mitochondrial autophagy dysfunction in dopaminergic neurons. This study was conducted to determine the role of PINK1 in the pathogenesis of postherpetic neuralgia (PHN) and find new targets for its treatment. A rigorous literature review was conducted to identify 2801 compounds from more than 200 plants in Asia. Virtual screening was used to shortlist the compounds into 20 groups based on their binding energies. MM/PBSA was used to further screen the compound dataset, and vitexin, luteoloside, and 2'-deoxyadenosine-5'-monophosphate were found to have a score of - 59.439, - 52.421, and - 47.544 kcal/mol, respectively. Pain behavioral quantification, enzyme-linked immunosorbent assay, quantitative polymerase chain reaction, western blotting, and transmission electron microscopy were used to confirm the effective mechanism. Vitexin had the most significant therapeutic effect on rats with PHN followed by luteoloside; 2'-deoxyadenosine-5'-monophosphate had no significant effect. Our findings suggested that vitexin could alleviate PHN by regulating mitochondrial autophagy through PINK1.

01 Oct 2024·Translational Cancer Research

Article

01 Jul 2023·Chemical Biology & Drug Design

Screening and introduction of key cell cycle microRNAs deregulated in colorectal cancer by integrated bioinformatics analysis

Article

Author: Sharifi, Kazem ; Firouzjaei, Ali Ahmadizad ; Aghaee‐Bakhtiari, Seyed Hamid ; Mohammadi‐Yeganeh, Samira ; Khazaei, Majid

AbstractColorectal cancer (CRC) is the second most common cancer in women and the third most common in men worldwide. Impaired cell cycle regulation leads to many cancers and is also approved in CRC. Therefore, cell cycle regulation is a critical therapeutic target for CRC. Furthermore, miRNAs have been discovered as regulators in a variety of cancer‐related pathways. This study is designed to investigate how miRNAs and mRNAs interact to regulate the cell cycle in CRC patients. Utilizing the Kyoto Encyclopedia of Genes and Genomes (KEGG), Gene Expression Omnibus (GEO), and Therapeutic Target Database (TTD), cell cycle‐associated genes were identified and evaluated. Seven of the 22 differentially expressed genes (DEGs) implicated in the cell cycle in three GSEs (GSE24514, GSE10950, and GSE74604) were identified as potential therapeutic targets. Then, using PyRx software, we performed docking proteins with selected drugs. The results demonstrated that these drugs are appropriate molecules for targeting cell cycle DEGs. Tarbase, miRTarbase, miRDIP, and miRCancer databases were used to find miRNAs that target the indicated genes. The ability of these six miRNAs to impact the cell cycle in colorectal cancer may be concluded. These miRNAs were found to be downregulated in SW480 cells when compared to the normal tissue. Our data imply that a precise selection of bioinformatics tools can facilitate the identification of miRNAs that impact mRNA translation at different stages of the cell cycle. The candidates can be investigated more as targets for cell cycle arrest in cancers.

100 Deals associated with Riviciclib

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Mantle cell lymphoma refractory	Phase 3	United States	Piramal Enterprises Ltd.	01 Nov 2009
Mantle cell lymphoma refractory	Phase 3	India	Piramal Enterprises Ltd.	01 Nov 2009
Locally Advanced Melanoma	Phase 3	India	Piramal Enterprises Ltd.	01 May 2009
Locally Advanced Melanoma	Phase 3	Australia	Piramal Enterprises Ltd.	01 May 2009
Locally Advanced Melanoma	Phase 3	New Zealand	Piramal Enterprises Ltd.	01 May 2009
Pancreatic Cancer	Phase 3	India	Piramal Enterprises Ltd.	01 May 2009
Locally Advanced Head and Neck Squamous Cell Carcinoma	Phase 3	India	Piramal Enterprises Ltd.	01 Sep 2008
Refractory Multiple Myeloma	Phase 3	India	Piramal Enterprises Ltd.	01 Jan 2008
Relapse multiple myeloma	Phase 3	India	Piramal Enterprises Ltd.	01 Jan 2008
Mucositis	Phase 3	-	Piramal Phytocare Ltd.	-

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT00843050 (CTgov)	Phase 2	Mantle cell lymphoma refractory	13	P276-00	aojxukumln(zyjoxzonhp) = qxqhuujhdn gldjkztovt (bhpnkqthxg, qucolmzrhh - vyhoehtjdi) View more	-	27 Jul 2012
AACR2009	Phase 1	Advanced cancer	47	P276-00	jjzgbdxhzy(vdjkptgkkw) = oxkhjjejww wjrcpsjkuj (cdnehmbyhg ) View more	-	01 May 2009